Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-19
    E.g., 2018-09-19

Archive Search

4 results
6:18 PM, Jun 09, 2011  |  BC Extra | Company News

FDA issues warning on BPH drugs

FDA said it updated the labels for 5-alpha reductase inhibitors to include information about an increased risk …
high-grade prostate cancer. Proscar and Avodart are approved to treat benign prostatic hyperplasia (BPH). Other 5-alpha reductase
5:56 PM, Jan 27, 2011  |  BC Extra | Company News

Complete response for GSK's Avodart

abstentions, that the benefit-risk profile of Avodart did not support approval for the indication. The 5-alpha reductase
5:27 PM, Dec 01, 2010  |  BC Extra | Company News

ODAC rebuffs Proscar, Avodart for prostate cancer

the Prostate Cancer Prevention Trial (PCPT) suggesting the drug reduces risk of the disease. The 5-alpha reductase
5:36 PM, Jun 15, 2010  |  BC Extra | Company News

EC conditionally approves Votrient

men with an enlarged prostate. The company expects to launch the fixed-dose combination of a 5-alpha reductase